基因重组毒素HELβ1-PE38KDEL与顺铂杀伤乳腺癌细胞系的协同作用

Synergistic effect between the recombined immunotoxin HELβ1-PE38KDEL and cisplatin in the cytotoxic effect against breast cancer cells

目的 :研究HELβ1 PE38KDEL与常规化疗药物顺铂杀伤乳腺癌细胞系的协同作用。 方法 :采用细胞增殖、软琼脂集落形成等实验 ,测定HELβ1 PE38KDEL和顺铂对高表达erbB2、3、4的乳腺癌细胞MDA MB 4 5 3,胃癌细胞N87的协同作用 ,并以低表达erbB2、3、4的乳腺癌细胞 2LMP为对照。结果 :HELβ1 PE38KDEL和顺铂联用对MDA MB 4 5 3和N87具有协同杀伤作用 (CI <1)。对 2LMP无协同作用 (CI >1)。结论 :对高表达erbB 2、3、4的乳腺癌细胞 ,基因重组毒素HELβ1 PE38KDEL与顺铂联用具有协同杀伤作用。

Purpose:To explore the synergistic effect of the combination between HELβ1-PE38KDEL and the conventional chemotherapy drug,cisplatin in the treatment against breast cancer cells.Methods:MTT and soft agar colony formation were used to detect the combination effect between HELβ1-PE38KDEL and cisplatin by MTT and soft agar colony formation in the breast cancer cell line MDA-MB-453 and gastric cancer cell line N87, which both have high expression of erbB2,3,4. Breast cancer cell line 2LMP with low expression of erbB2,3,4 was chosen as control. Results:There was synergistic effect between HELβ1-PE38KDEL and cisplatin in breast cancer cell line MDA-MB-453 and gastric cancer cell N87 by the experiment in vitro (CI<1). In contrast, no synergistic effect was found in 2 LMP(CI>1). Conclusions:Synergistic effect was disclosed in the combination of recombined immunotoxin HELβ1-PE38KDEL and cis-platin in the therapy against breast cancer cell with high expression of erbB-2,3,4.